HRP20180116T1 - (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i - Google Patents

(2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i Download PDF

Info

Publication number
HRP20180116T1
HRP20180116T1 HRP20180116TT HRP20180116T HRP20180116T1 HR P20180116 T1 HRP20180116 T1 HR P20180116T1 HR P20180116T T HRP20180116T T HR P20180116TT HR P20180116 T HRP20180116 T HR P20180116T HR P20180116 T1 HRP20180116 T1 HR P20180116T1
Authority
HR
Croatia
Prior art keywords
carboxamide
ethyl
cyano
phenyl
oxo
Prior art date
Application number
HRP20180116TT
Other languages
English (en)
Croatian (hr)
Inventor
Hans Roland Lönn
Stephen Connolly
Steven Swallow
Staffan PO KARLSSON
Carl-Johan Aurell
John Fritiof PONTÉN
Kevin James Doyle
Amanda Jane Van De Poël
Graham Peter Jones
David Wyn Watson
Jacqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20180116T1 publication Critical patent/HRP20180116T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20180116TT 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i HRP20180116T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
EP15701577.7A EP3097086B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
HRP20180116T1 true HRP20180116T1 (hr) 2018-03-23

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20250302TT HRP20250302T1 (hr) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i
HRP20180116TT HRP20180116T1 (hr) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i
HRP20201147TT HRP20201147T1 (hr) 2014-01-24 2020-07-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20250302TT HRP20250302T1 (hr) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20201147TT HRP20201147T1 (hr) 2014-01-24 2020-07-23 (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i

Country Status (39)

Country Link
US (18) US9522894B2 (enExample)
EP (4) EP3744714B1 (enExample)
JP (7) JP6469711B2 (enExample)
KR (1) KR102417684B1 (enExample)
CN (2) CN110483492B (enExample)
AP (1) AP2016009322A0 (enExample)
AR (1) AR099177A1 (enExample)
AU (4) AU2015208932C1 (enExample)
BR (1) BR112016016224B1 (enExample)
CA (1) CA2935625C (enExample)
CL (1) CL2016001889A1 (enExample)
CR (1) CR20160327A (enExample)
CY (2) CY1120049T1 (enExample)
DK (3) DK3097086T3 (enExample)
DO (1) DOP2016000175A (enExample)
EA (1) EA032794B1 (enExample)
ES (3) ES2658516T3 (enExample)
FI (1) FI3744714T3 (enExample)
HK (1) HK1225730B (enExample)
HR (3) HRP20250302T1 (enExample)
HU (3) HUE070606T2 (enExample)
IL (3) IL246614B (enExample)
LT (3) LT3744714T (enExample)
MX (1) MX368840B (enExample)
MY (1) MY194850A (enExample)
NO (1) NO2699580T3 (enExample)
NZ (2) NZ722063A (enExample)
PE (1) PE20161218A1 (enExample)
PH (1) PH12016501439A1 (enExample)
PL (3) PL3097086T3 (enExample)
PT (3) PT3323814T (enExample)
RS (3) RS56919B1 (enExample)
SG (2) SG10201701056QA (enExample)
SI (3) SI3097086T1 (enExample)
SM (3) SMT202000433T1 (enExample)
TW (1) TWI690517B (enExample)
UY (1) UY35963A (enExample)
WO (1) WO2015110826A1 (enExample)
ZA (2) ZA201605856B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) * 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis
US12059424B2 (en) * 2018-03-01 2024-08-13 Astrazeneca Ab Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
JP2021530513A (ja) * 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
AU2019306532A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
PH12022550895A1 (en) * 2019-10-23 2023-03-27 Chong Kun Dang Pharmaceutical Corp Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
WO2022020245A1 (en) * 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
HRP20241656T1 (hr) * 2020-08-26 2025-02-14 Haisco Pharmaceuticals Pte. Ltd. Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
WO2022117059A1 (zh) 2020-12-04 2022-06-09 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
AU2022376535A1 (en) * 2021-10-29 2024-05-02 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
CN118475575A (zh) * 2022-01-11 2024-08-09 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
IL314769A (en) * 2022-02-16 2024-10-01 Insmed Inc Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
JP2025505824A (ja) * 2022-02-22 2025-02-28 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ１阻害剤結晶多形体及びその製造方法と用途
US20250179060A1 (en) * 2022-02-22 2025-06-05 Haisco Pharmaceuticals Pte. Ltd. Preparation method of nitrogen-containing heterocyclic compound
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
AU2023285191A1 (en) * 2022-06-07 2024-12-12 Reistone Biopharma Company Limited Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
US20250353839A1 (en) * 2022-06-07 2025-11-20 Reistone Biopharma Company Limited Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
JPWO2023243601A1 (enExample) 2022-06-13 2023-12-21
EP4551554A1 (en) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en) 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
WO2024148308A1 (en) * 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
CN120693326A (zh) * 2023-02-15 2025-09-23 英斯梅德股份有限公司 某些1，4-氧杂氮杂环庚烷-2-甲酰胺作为dpp1抑制剂的用途
KR20250164714A (ko) * 2023-03-23 2025-11-25 하이스코 파마수티컬즈 피티이. 엘티디. 디펩티딜 펩티다제 저분자 억제제를 함유하는 약학적 조성물
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (en) 2000-09-08 2002-03-14 Prozymex A/S Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
PT1323710E (pt) * 2000-10-06 2008-11-25 Mitsubishi Tanabe Pharma Corp Compostos azotados com anel de cinco membros
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CA2467435A1 (en) 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
ES2308181T3 (es) 2003-05-30 2008-12-01 Prozymex A/S Inhibidores de proteasa.
US20070099958A1 (en) * 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
PT1732949E (pt) 2004-04-07 2010-03-23 Univ Minnesota Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
NZ552208A (en) 2004-06-29 2008-11-28 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
ES2464281T3 (es) 2004-07-19 2014-06-02 The Johns-Hopkins University Inhibidores de FLT3 para la inmunosupresión
KR20190062506A (ko) 2005-02-18 2019-06-05 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
CA2611688A1 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
US7691851B2 (en) 2007-03-07 2010-04-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
CA2700534A1 (en) 2007-09-25 2009-04-02 Novartis Ag Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009074829A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
WO2010114405A2 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
JP2012526093A (ja) * 2009-05-07 2012-10-25 アストラゼネカ・アクチエボラーグ 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
PL3150198T3 (pl) 2010-04-07 2022-01-17 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksamido)-3-metylopirydyn-2-ylo)benzoesowego i ich podawanie
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
PH12013501665A1 (en) 2011-02-11 2019-07-17 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
MX355055B (es) 2012-04-17 2018-04-03 Astellas Pharma Inc Compuesto heterociclico aromatico biciclico nitrogenado.
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX363936B (es) 2013-03-14 2019-04-09 Boehringer Ingelheim Int (bencil-ciano-metil)-amidas del acido 2-aza-biciclo[2.2.1]heptano- 3-carboxilico sustituidas como inhibidores de catepsina c.
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
US9856228B2 (en) 2013-09-09 2018-01-02 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
US20170027907A1 (en) 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
BR112016026699B1 (pt) 2014-05-15 2022-09-13 Insmed Incorporated Uso de uma composição farmaceutica de amicacina ou de um sal farmaceuticamente aceitável desta
CN107075557B (zh) 2014-05-30 2021-07-06 香港大学 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
RS59444B1 (sr) 2014-09-12 2019-11-29 Boehringer Ingelheim Int Spirociklični inhibitori katepsina c
MX370366B (es) 2014-11-14 2019-12-11 Boehringer Ingelheim Int Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4).
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2018022978A1 (en) 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
US20190247400A1 (en) 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis
US12059424B2 (en) 2018-03-01 2024-08-13 Astrazeneca Ab Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
JP2021530513A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
KR20220022115A (ko) 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
US20240226112A1 (en) 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
AU2022376535A1 (en) 2021-10-29 2024-05-02 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
IL314769A (en) 2022-02-16 2024-10-01 Insmed Inc Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
SMT202500137T1 (it) 2025-05-12
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
LT3323814T (lt) 2020-10-26
HK1255870A1 (en) 2019-08-30
DK3744714T3 (da) 2025-04-07
LT3744714T (lt) 2025-04-10
DK3323814T3 (da) 2020-08-03
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
US20230115170A1 (en) 2023-04-13
US20200017455A1 (en) 2020-01-16
CR20160327A (es) 2016-10-20
US20210238152A1 (en) 2021-08-05
AP2016009322A0 (en) 2016-07-31
JP6469711B2 (ja) 2019-02-13
US20230085620A1 (en) 2023-03-23
SG11201606052TA (en) 2016-08-30
SMT202000433T1 (it) 2020-09-10
EA032794B1 (ru) 2019-07-31
CN105980367B (zh) 2019-08-23
US20230069044A1 (en) 2023-03-02
US20180251436A1 (en) 2018-09-06
CN105980367A (zh) 2016-09-28
NO2699580T3 (enExample) 2018-02-24
AU2018202956B2 (en) 2019-05-09
JP2023156479A (ja) 2023-10-24
AU2017200338B2 (en) 2018-03-01
CA2935625C (en) 2022-10-18
US11655222B2 (en) 2023-05-23
CY1120049T1 (el) 2018-12-12
US12054465B2 (en) 2024-08-06
MX368840B (es) 2019-10-18
JP7714823B2 (ja) 2025-07-29
RS66709B1 (sr) 2025-05-30
PL3097086T3 (pl) 2018-04-30
TWI690517B (zh) 2020-04-11
MY194850A (en) 2022-12-19
PT3744714T (pt) 2025-04-07
JP2017503832A (ja) 2017-02-02
AU2015208932B2 (en) 2017-02-16
AR099177A1 (es) 2016-07-06
US10287258B2 (en) 2019-05-14
AU2015208932B8 (en) 2017-03-09
US11814359B2 (en) 2023-11-14
EP3097086A1 (en) 2016-11-30
PL3744714T3 (pl) 2025-09-08
US11117874B2 (en) 2021-09-14
AU2015208932C1 (en) 2017-05-25
HUE070606T2 (hu) 2025-06-28
CL2016001889A1 (es) 2016-12-09
SMT201800058T1 (it) 2018-03-08
SG10201701056QA (en) 2017-03-30
CA2935625A1 (en) 2015-07-30
ES3018635T3 (es) 2025-05-16
KR20160111470A (ko) 2016-09-26
JP7157791B2 (ja) 2022-10-20
US20150210655A1 (en) 2015-07-30
BR112016016224A2 (enExample) 2017-08-08
US20230116721A1 (en) 2023-04-13
EP3097086B1 (en) 2017-12-13
EP4548972A2 (en) 2025-05-07
EA201691375A1 (ru) 2017-01-30
CN110483492A (zh) 2019-11-22
US10669245B2 (en) 2020-06-02
WO2015110826A1 (en) 2015-07-30
MX2016009349A (es) 2016-10-13
EP3323814B1 (en) 2020-05-13
EP3323814A1 (en) 2018-05-23
NZ734768A (en) 2022-09-30
PL3323814T3 (pl) 2020-10-19
AU2019202675B2 (en) 2020-05-28
AU2019202675A1 (en) 2019-05-16
SI3744714T1 (sl) 2025-05-30
CN110483492B (zh) 2023-07-21
US20240132455A1 (en) 2024-04-25
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (en) 2025-06-25
JP2019070029A (ja) 2019-05-09
US20200247765A1 (en) 2020-08-06
SI3323814T1 (sl) 2020-10-30
US20230062646A1 (en) 2023-03-02
BR112016016224B1 (pt) 2023-02-23
NZ722063A (en) 2017-09-29
US20170057938A1 (en) 2017-03-02
US20230250071A1 (en) 2023-08-10
EP3744714B1 (en) 2025-01-15
TW201612167A (en) 2016-04-01
US11673871B2 (en) 2023-06-13
US11673872B2 (en) 2023-06-13
US11680049B2 (en) 2023-06-20
US11655224B2 (en) 2023-05-23
PT3323814T (pt) 2020-08-05
US11655223B2 (en) 2023-05-23
AU2018202956A1 (en) 2018-05-17
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
US11667615B2 (en) 2023-06-06
JP2025072423A (ja) 2025-05-09
AU2015208932A8 (en) 2017-03-09
US20230033573A1 (en) 2023-02-02
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
JP6804570B2 (ja) 2020-12-23
JP2025157389A (ja) 2025-10-15
HUE052421T2 (hu) 2021-04-28
ES2658516T3 (es) 2018-03-12
CY1123391T1 (el) 2021-12-31
US20240336582A1 (en) 2024-10-10
US11655221B2 (en) 2023-05-23
JP2021046423A (ja) 2021-03-25
ZA201800431B (en) 2019-09-25
PH12016501439B1 (en) 2017-02-06
HRP20201147T1 (hr) 2020-12-11
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
ZA201605856B (en) 2020-02-26
RS60639B1 (sr) 2020-09-30
HK1225730B (en) 2017-09-15
LT3097086T (lt) 2018-02-26
DOP2016000175A (es) 2016-08-15
US20230025351A1 (en) 2023-01-26
SI3097086T1 (en) 2018-04-30
JP7336563B2 (ja) 2023-08-31
US9522894B2 (en) 2016-12-20
JP2022096662A (ja) 2022-06-29
KR102417684B1 (ko) 2022-07-05
PE20161218A1 (es) 2016-11-27
PH12016501439A1 (en) 2017-02-06
US9815805B2 (en) 2017-11-14
HRP20250302T1 (hr) 2025-04-25
IL265611A (en) 2019-05-30
DK3097086T3 (en) 2018-02-05
US20230028726A1 (en) 2023-01-26
IL252836A0 (en) 2017-08-31
US20230278969A1 (en) 2023-09-07
JP7628587B2 (ja) 2025-02-10

Similar Documents

Publication Publication Date Title
HRP20180116T1 (hr) (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i
NZ596071A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
AR080746A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp.
PH12019501098A1 (en) Pyrrolopyrimidines as cftr potentiators
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP2014511892A5 (enExample)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
NO20054206L (no) Bifenylderivater
TN2012000139A1 (en) Cgrp receptor antagonists
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
JP2013543896A5 (enExample)
RU2009126624A (ru) Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
NZ724602A (en) Ror-gamma modulators and uses thereof
JP2017526636A5 (enExample)
EA201490453A1 (ru) Замещенные аналоги (e)-n-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
CA2554642A1 (en) Bicyclic carbonyl amino derivatives as chemokine receptor antagonists
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
MX2021010133A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada.
JP2017519835A5 (enExample)
CA2610354A1 (en) Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
JP2017500321A5 (enExample)
JP2015504874A5 (enExample)
AR109652A1 (es) Métodos para utilizar agonistas de fxr